Pfizer: positive phase 3 results for Talzenna

(CercleFinance.com) - Pfizer Inc.
today announced positive top-line results from the Talzenna (talazoparib) Phase 3 TALAPRO-2 trial.

The study met its primary endpoint, with a significant improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in metastatic prostate cancer, non-metastatic prostate cancer and metastatic castration-sensitive prostate cancer (mCPC)

Results showed a trend toward improved overall survival, a key secondary endpoint, at the time of analysis, but these data are not yet mature.

Additional secondary endpoints are under analysis.

These data underscore the potential for Talzenna in combination with XTANDI to become a new standard of care for mCRPC, Pfizer said, adding that it believes Talzenna in prostate cancer could become the next potential blockbuster opportunity in its leading Pfizer Oncology portfolio.


Copyright (c) 2022 CercleFinance.com. All rights reserved.